Stem Cell ClinicsStem Cell Treatments

Its important to recognize that the pace of medical discovery is nothing less than amazing. Initially, there was complete ignorance of stem cells. Then there was the birth of stem cell therapy in the 70-80s, limited to cancers of the blood/lymph system and now as with all changes, there initially is a disbelief period followed by experimental and unproven claims and then finally acceptance. Arthur C. Clarke stated it well, New ideas pass through three periods: 1) It cant be done. 2) It probably can be done, but its not worth doing. 3) I knew it was a good idea all along! We are currently experiencing mild acceptance that stem cell therapy is a medical procedure with potentials. The old school anti-clinical applications groups remain vocal, however they are quickly loosing their impact.

At present the forces of big pharma and regulatory agencies (read the FDA) are dictating your choices, based on the lost revenue models that stem cell therapies may impact, in the US. There is a study suggesting that the stem cell industry will rise to 10% of the current pharmaceutical industrys net revenue in the next 10 years. This represents a 9 Billion dollar challenge to this entrenched big phama, clearly a formable business concern. For those of you interested in the methods of restraint used, read the Code of Federal Regulations Title 21 part 1271. The key words are minimal manipulation and those surrounding the definition of a drug. Your cells become a drug with even a smidgen of treatment and require the full testing and 10+ years of development.

Internationally there has been a much more favorable attitude and many of the most important steps forward are made overseas. The predominant attitude of many international governments is that the implosion of the health care industry in the US will lead to an explosion of medical tourism. A recent survey has foreign hospitals clamoring to achieve JCAHO certification, which stands for Joint Commission on Accreditation of Healthcare Organizations, to assure the public of their quality control. This organization evaluates and certifies hospitals to meet standards and receive Medicare/Medicade funding.

Curiously, many of the tools of the stem cell trade are manufactured in the US. However, the same firms can sell the products domestically if used only for research. They collect a certification statement to this effect, when selling in the US.

Its vitally important that as a consumer of medical services you chose a facility that is unequivocally interested in both an appropriate and well delivered level of services. There are, as with any procedures, risks and benefits. The practice of medicine is both an art and science and requires the correct practitioner, laboratory support and coordination team to provide the highest level of care possible.

This checklist is intended to give you a more precise approach, toward making your medical decisions. Please excuse its length, however a more specific and all encompassing look at this important decision is very significant.

1. There are no guarantees in medicine. The understanding of how the human body functions is still not fully understood. At this time stem cell therapies are not offered as a cure for any disease or a substitute for other forms of care. One of the most potentially misleading approaches to selling medical procedures is the use of anecdotal evidence or personal experiences, regardless of how miraculous they appear. The response of a patient is so individual in nature, without scientific study and collection of data, as to be only a sign of a potential, not proof of a treatments overall effect. ___

2. Does a specific board-certified physician perform the procedures? There are many levels of expertise and only an experienced physician, in the field specific to your disease, should be involved. A board of advisers is helpful and appropriate to have a better opportunity to keep up with the fast pace of medicine, but these individuals are not those administering the actual procedures. ___

3. Are the clinics physicians in compliance with existing medical laws? Although this may seem a strange question, consider the Mexican laws. There they issue a very limited number of licenses, specifically for stem cells, with both allogeneic and autologous limitations. Ask to see a picture of these certifications and check who is listed. Many countries have no regulation and allow any type of physician to perform the procedures. ___

4. Personal experiences with a clinic in regards to their delivery of services, facilities, and personnel should not be relied upon to make a decision for treatment. Its important to feel comfortable, particularly in a foreign country where you will need assistance to navigate and express your needs. At World Stem Cells Clinic we pride ourselves in paving the way toward making your treatments as smooth an experience as possible. Our well-trained team assists you from the start, at the time of contact at the airport, to end of the treatment and with follow-up thereafter. ___

Follow this link:
Stem Cell ClinicsStem Cell Treatments

Comments Off

Stem Cells – Jeunesse

New cell growth is an essential part of lifeits how we grow from child to adult. But as we age and our growing decelerates, so does the production of new cells. At the same time, our bodys cells themselves age and their functions begin to slow. When it comes to your skin, this can lead to a dull, sagging complexion on the outside and cells that cant efficiently accept nutrients and remove toxins on the inside.

Part of Y.E.S.

The science of stem cells

The power behind LUMINESCE

Read more:
Stem Cells – Jeunesse

Comments Off

Stem Cells | The Ellison Medical Foundation

A Purkinje neuron in the cerebellum of a mouse. After a bone marrow transplant, two donor-derived cells were found in the brain of the recipient mouse

James Weimann from Weimann JM, Johansson CB, Trejo A, & Blau HM, (2003). Stable reprogrammed heterokaryons form spontaneously in Purkinje neurons after bone marrow transplant.Nature Cell Biology 5, 959-966.

Regardless of the source of stem cells, there are problems that must be solved to turn them into agents for healing damage in tissues.

– Stuart A. Lipton

So much sturm und drang has been spent on whether to create new embryonic stems cells for research vs. reprogramming adult stem cells to seek the same ends that the real promise of stem cell research remains submerged in controversy.*

Clear answers are not yet in on which approach is best. Still, most observers would agree that doing both kinds of experiments is essential. Much is being learned from adult stem cell research that might be applied to cultured embryos, and vice versa.

One of the golden goals of such work is to someday be able to safely replace damaged or ill tissues, or even whole organs. So, do you start with adult stem cells that are already programmed to make a certain cell type, such as renal tissue? Or do you go all the way back to square one, using embryonic stem cells even totipotent cells to generate younger, highly specific tissue types that can be used therapeutically? Is it faster and easier to start from scratch? Or might cells that are already halfway there, already committed to a certain cell lineage, be a better starting place? Also, might adult stem cells be less immunogenic, less likely to be rejected, when re-implanted into their original, familiar host?

Research hasnt provided many satisfying answers yet. But the picture may soon change dramatically since federal regulations in the U.S. started being modified to allow creation of new embryonic stem cell lines for research. This change is likely to greatly speed up the pace of experimentation, as will the flow of federal money meant to spur embryonic stem cell work.

The politically motivated restrictions imposed upon researchers limiting research to only use a few already-established embryonic cell lines, plus prohibiting federal funding for most embryonic stem cell research severely hampered U.S. stem cell experimentation, inadvertently allowing research teams in the United Kingdom, Korea, Japan and elsewhere gain a strong head-start in this new biotechnical industry. Fortunately, some states such as California responded by setting up stem cell research programs of their own free of federal restrictions hoping to help keep U.S.-based researchers competitive.

In any case, the latest stem cell results coming from The Ellison Medical Foundation scholars show that stem cells of either type embryonic or adult are dependent on vital information gleaned from their surroundings. Stem cells, like all other cells, need to know who they are, where they came from and who their neighbors are. In other words, each cell lives in a particular niche, and its the flow of positional information via growth factors and other signaling molecules from neighbors, that tells stem cells what they should be doing, even whether to live or die. So sciences important task now is to decode, understand and manipulate all this inter-cellular signaling.

Originally posted here:
Stem Cells | The Ellison Medical Foundation

Comments Off

Stem cell transplantation for articular cartilage repair …

Mesenchymal stem cells (MSCs) are pluripotent cells found in multiple human adult tissues including bone marrow, synovial tissues, and adipose tissues. Since they are derived from the mesoderm, they have been shown to differentiate into bone, cartilage, muscle, and adipose tissue.[1] MSCs from embryonic sources have shown promise scientifically while creating significant controversy. As a result, many researchers have focused on adult stem cells [1], or stem cells isolated from adult humans that can be transplanted into damaged tissue.

Because of their multi-potent capabilities, mesenchymal stem cell (MSC) lineages have been used successfully in animal models to regenerate articular cartilage and in human models to regenerate bone.[2][3][4] Recent research demonstrates that articular cartilage may be able to be repaired via percutaneous introduction of mesenchymal stem cells (MSCs).[5]

Research into MSCs has exploded in recent years. As an example, a PubMed search for the year 1999 reveals about 90 papers published under the MESH heading of Mesenchymal Stem Cells, the same search ran for the year 2007 reveals more than 4,000 entries. The most commonly used source of MSCs is bone marrow aspirate. Most of the adult bone marrow consists of blood cells in various stages of differentiation.[6] These marrow components can be divided into plasma, red blood cells, platelets, and nucleated cells. The adult stem cell fraction is present in the nucleated cells of the marrow. Most of these cells are CD34+ heme progenitors (destined to differentiate into blood components), while very few are actually MSCs capable of differentiating into bone, cartilage, or muscle. As a result, that leaves the very small number of MSCs in the marrow as cells capable of differentiating into tissues of interest to joint preservation.[7] Of note, this may be one of the reasons that commercially available centrifuge systems that concentrate marrow nucleated cells have not shown as much promise in animal research for cartilage repair as have approaches where MSCs are expanded in culture to greater numbers.

Marrow nucleated cells are used every day in regenerative orthopedics. The knee microfracture surgery technique popularized by Steadman[8] relies on the release of these cells into a cartilage lesion to initiate fibrocartilage repair in osteochondral defects.[9] In addition, this cell population has also been shown to assist in the repair of non-union fractures.[10] For this application, bed side centrifugation is commonly used. Again, these techniques produce a very dilute MSC population, usually a yield of 1 in 10,000-1,000,000 of the nucleated cells.[11] Despite this low number of MSCs, isolated bone marrow nucleated cells implanted into degenerated human peripheral joints have shown some promise for joint repair.[12] As the number of MSCs that can be isolated from bone marrow is fairly limited, most research in cartilage regeneration has focused on the use of culture expanded cells.[13][14] This method can expand cell numbers by 100-10,000 fold over several weeks. Once these MSCs are ready for re-implanation, they are usually transferred with growth factors to allow for continued cell growth and engraftment to the damaged tissue. At some point, a signal is introduced (either in culture or after transplant to the damaged tissue) for the cells to differentiate into the end tissue (in this discussion, cartilage).

Until recently, the use of cultured mesenchymal stem cells to regenerate cartilage has been primarily in research with animal models. There are now, however, two published case reports of the above technique being used to successfully regenerate articular and meniscus cartilage in human knees.[15][16] This technique has yet to be shown effective in a study involving a larger group of patients, however the same team of researchers have published a large safety study (n=227) showing fewer complications than would normally be associated with surgical procedures. [17]

Another team used a similar technique for cell extraction and ex vivo expansion but cells were embedded within a collagen gel before being surgically re-implanted. They reported a case study in which a full-thickness defect in the articular cartilage of a human knee was successfully repaired.[18]

While the use of cultured mesenchymal stem cells has shown promising results, a more recent study using uncultured MSCs has resulted in full thickness, histologically confirmed hyaline cartilage regrowth. Dr. Khay-Yong Saw and his team evaluated the quality of the repair knee cartilage after arthroscopic microdrilling (also microfracture) surgery followed by post-operative injections of autologous peripheral blood progenitor cells (PBPC) in combination with hyaluronic acid(HA).[19] PBPCs are a blood product containing MSCs, which is obtained by mobilizing stem cells into the peripheral blood. In February 2011, the team published the results of a 5 patient case series. All five patients showed evidence of hyaline cartilage regeneration at second-look arthroscopy and subsequent biopsy, including 2 patients with full thickness bipolar or kissing lesions. The authors propose that the microdrilling surgery creates a blood clot scaffold on which injected PBPCs can be recruited and enhance chondrogenesis at the site of the contained lesion. They explain that the significance of this cartilage regeneration protocol is that it is successful in patients with historically difficult-to-treat grade IV bipolar or bone-on-bone osteochondral lesions.

Dr. Saw and his team are currently conducting a larger randomized trial and working towards beginning a multicenter study. The work of the Malaysian research team is gaining international attention.[20]

View post:
Stem cell transplantation for articular cartilage repair …

Comments Off

Stem Cell Research News, Photos and Videos – ABC News

Robin Roberts Gets Laughs on ‘Letterman’

immune system to the brink. And then, my dear sister, sally, she had healthy stem cells that were compatible. And she was a perfect match. They insert her stem cells into me. You’re sitting here, not just with me, but with my sister, as

Continue reading here:
Stem Cell Research News, Photos and Videos – ABC News

Comments Off

Stem cells to treat blindness may be safe

LONDON (AP) An experimental treatment for blindness that uses embryonic stem cells appears to be safe, and it improved vision in more than half of the patients who got it, two early studies show.

Researchers followed 18 patients for up to three years after treatment. The studies are the first to show safety of an embryonic stem cell treatment in humans for such a long period.

Its a wonderful first step but it doesnt prove that (stem cells) work, said Chris Mason, chair of regenerative medicine at University College London, who was not part of the research. He said it was encouraging the studies proved the treatment is safe and dispelled fears about stem cells promoting tumor growth.

Embryonic stem cells, which are recovered from embryos, can become any cell in the body. They are considered controversial by some because they involve destroying an embryo and some critics say adult stem cells, which are derived from tissue samples, should be used instead.

Scientists have long thought about transforming them into specific types of cells to help treat various diseases. In the new research, scientists turned stem cells into retinal cells to treat people with macular degeneration or Stargardts macular dystrophy, the leading causes of blindness in adults and children.

In each patient, the retinal cells were injected into the eye that had the worst vision. Ten of the 18 patients later reported they could see better with the treated eye than the other one. No safety problems were detected. The studies were paid for by the U.S. company that developed the treatment, Advanced Cell Technology, and were published online Tuesday in the journal, Lancet.

Dr. Robert Lanza, one of the study authors, said it was significant the stem cells survived years after the transplant and werent wiped out by the patients own immune systems. For some of the patients, Lanza noted their improved vision changed their lives, referring to a 75-year-old horse rancher who had been blind in one eye before the treatment.

One month after his treatment, his vision had improved (substantially) and he can even ride his horses again, Lanza said in an email. He said other patients have regained their independence with their newfound vision and said some people are now able to use their computers again, read their watches or travel on their own.

The next step will be to prove these (stem cell) treatments actually work, Mason said. Unless there is a sham group where you inject saline into (patients) eyes, we cant know for sure that it was the stem cells that were responsible.

Link:
Stem cells to treat blindness may be safe

Comments Off

Stem Cells Create a Therapeutic Niche | Page 2

Exciting, albeit controversial, results of human cloning were recently published in the journal Cell Stem Cell following collaborative research conducted by scientists at the CHA Stem Cell Institute in Seoul, Korea, the Research Institute for Stem Cell Research (a part of the CHA Health Systems), and the company Advanced Cell Technology. The scientists reprogrammed an egg cell by removing its DNA and replacing it with nuclei from two adult donors aged 35 years and 75 years. The experimental procedures could successfully generate two karyotypically normal diploid ESC lines. This technique had previously been developed, but with infant/fetal donor cells, which, unlike adult cells, are not associated with agerelated changes such as shortened telomerases and oxidative DNA damage.9 iPSCs Extracting and then maintaining adult stem cells in the laboratory is extremely difficult, as they have a limited capacity to divide in culture.5 The discovery of the transdifferentiation process of adult stem cells, wherein adult stem cells are subjected to certain differentiation techniques to generate cell types different from the predicted types, was therefore very exciting.8

Taking the process a step further, researchers in Japan developed a technique to reprogram normal adult cells into stem cells, the iPSCs, by the forced introduction of a set of transcription factors into the cells.10 These transcription factors (different combinations of Oct4, Sox2, Klf4, c-Myc, Nanog, Lin28) regulate important steps in early embryonic development and force the adult somatic cells into an embryonic stem celllike state. This technique has essentially revolutionized the field of regenerative medicine; the patient himself could now be an unlimited source of immune-matched pluripotent cells.11

As promising as the therapy sounds, it is riddled with its own problems. It has always been known that the genes that regulate developmental pathways also regulate cancer, and are especially potent when expressed in combination. Therefore, researchers have trimmed the initial group of four transcription factors down to two, with the aim of simultaneously treating the cells with various chemicals to boost reprogramming efficiency. Additionally, the use of either lentiviruses or retroviruses (Figure 2) to introduce the genes into the host cell can result in uncontrolled effects of viral integration. Current efforts are directed toward reprograming cells without viruses or using more efficient integration techniques.11

iPSCs indicates induced pluripotent stem cells. Adapted from: Regenerative Medicine. Department of Health and Human Services. http://stemcells.nih.gov/info/scireport/ Pages/2006report.aspx. Published August 2006. Accessed April 4 2014.

A new iPSC transplantation therapy will also be evaluated for safety in patients with Parkinson disease. Jun Takahashi, MD, PhD, and his colleagues at the Kyoto Universitys Center for iPS Cell Research and Application have successfully developed a technique to generate dopamine-producing nerve cells from patient-derived iPSCs for transplantation into the patients brain, an attempt at regenerating the damaged dopaminergic neurons.13 When contacted by e-mail, Takahashi responded that they are currently conducting preclinical studies, the results from which will be submitted for approval prior to initiating clinical trials.

In a novel approach, researchers at the RIKEN Research Center for Allergy and Immunology reported the generation of cancer-specific killer T cells from iPSCs. The human body has a natural ability to produce tumor-specific cytotoxic T lymphocytes, which when activated are effective but not sufficient to cure the patient, due to their short life span. To tackle this problem, the scientists reprogrammed T cells into iPSCs, which were further manipulated to differentiate into mature T cells. Although the tools are ready, they have not yet been tested in vitro or in vivo for their cancer cellkilling potential.14

Here is the original post:
Stem Cells Create a Therapeutic Niche | Page 2

Comments Off

Researchers Develop New Cells Meant to Form Blood Vessels, Treat Peripheral Artery Disease

Contact Information

Available for logged-in reporters only

Newswise INDIANAPOLIS — Researchers have developed a technique to jump-start the body’s systems for creating blood vessels, opening the door for potential new treatments for diseases whose impacts include amputation and blindness.

The international team, led by scientists at the Indiana University School of Medicine, is targeting new therapies for illnesses such as peripheral artery disease, a painful leg condition caused by poor blood circulation. The disease can lead to skin problems, gangrene and sometimes amputation.

While the body has cells that specialize in repairing blood vessels and creating new ones, called endothelial colony-forming cells, these cells can lose their ability to proliferate into new blood vessels as patients age or develop diseases like peripheral arterial disease, said Mervin C. Yoder Jr., M.D., Richard and Pauline Klingler Professor of Pediatrics at IU and leader of the research team.

Peripheral artery disease patients can be given medication to improve blood flow, but if the blood vessels to carry that improved flow are reduced in number or function, the benefits are minimal. If “younger,” more “enthusiastic” endothelial colony forming cells could be injected into the affected tissues, they might jump-start the process of creating new blood vessels. Gathering those cells would not be easy however — they are relatively difficult to find in adults, especially in those with peripheral arterial disease. However, they are present in large numbers in umbilical cord blood.

Reporting their work in the journal Nature Biotechnology, the researchers said they had developed a potential therapy through the use of patient-specific induced pluripotent stem cells, which are normal adult cells that have been “coaxed” via laboratory techniques into reverting into the more primitive stem cells that can produce most types of bodily tissue. So, in one of the significant discoveries reported in the Nature Biotechnology paper, the research team developed a novel methodology to mature the induced pluripotent stem cells into cells with the characteristics of the endothelial colony-forming cells that are found in umbilical cord blood. Those laboratory-created endothelial colony-forming cells were injected into mice, where they were able to proliferate into human blood vessels and restore blood flow to damaged tissues in mouse retinas and limbs.

Overcoming another hurdle that has been faced by scientists in the field, the research team found that the cord-blood-like endothelial colony-forming cells grown in laboratory tissue culture expanded dramatically, creating 100 million new cells for each original cell in a little less than three months.

“This is one of the first studies using induced pluripotent stem cells that has been able to produce new cells in clinically relevant numbers — enough to enable a clinical trial,” Dr. Yoder said. The next steps, he said, include reaching an agreement with a facility approved to produce cells for use in human testing. In addition to peripheral artery disease, the researchers are evaluating the potential uses of the derived cells to treat diseases of the eye and lungs that involve blood flow problems.

A short video explaining the research is available here: http://youtu.be/nyPk_5bLdzs

Read more:
Researchers Develop New Cells Meant to Form Blood Vessels, Treat Peripheral Artery Disease

Comments Off

BioTimes Subsidiary Cell Cure Neurosciences Ltd. Files an IND with the FDA for OpRegen Designed to Treat Patients …

The design of the proposed clinical trial, Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients with Advanced Dry-Form Age-Related Macular Degeneration with Geographic Atrophy, is based on a pre-IND meeting with the FDA and a series of earlier interactions with the agency. Patients will undergo a single transplantation and the study will explore three different doses of OpRegen. Following transplantation, the patients will be followed over 12 months at specified intervals and then at longer time periods, to evaluate the safety and tolerability of the product. A secondary objective of the clinical trial will be to explore the ability of transplanted OpRegen to engraft, survive, and moderate the disease progression.

The filing of this IND is the culmination of 12 years of research and development starting at the Hadassah Human Embryonic Stem Cell Research Center at Hadassah University Medical Center, Jerusalem, Israel, under the direction of Prof. Benjamin Reubinoff, MD, PhD and continuing at Cell Cure Neurosciences Ltd., said Charles S. Irving Ph.D., Cell Cures CEO. We look forward to initiating the clinical trial that will, for the first time, utilize xeno-free grade human embryonic stem cell derived RPE cells with high purity and potency, for the treatment of geographic atrophy, the severe stage of dry-AMD.

About Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is one of the major diseases of aging and is the leading eye disease responsible for visual impairment of older persons in the US, Europe and Australia. AMD affects the macula, which is the part of the retina responsible for sharp, central vision that is important for facial recognition, reading and driving. There are two forms of AMD. The dry form (dry-AMD) advances slowly and painlessly until it progresses to the severe form called geographic atrophy (GA). Once the atrophy reaches the fovea (the center of the macula), patients lose their central vision and may develop legal blindness. There is currently no effective treatment for dry-AMD. There are about 1.6 million new cases of dry-AMD in the US annually. The yearly economic loss to the gross domestic product in the United States from dry-AMD has been estimated to be $24.4 billion. The market opportunity for a treatment for GA has been estimated at over $5 billion globally. About 10% of patients with dry-AMD develop wet-AMD, which is an acute disease and can lead to severe visual loss in a matter of weeks. Wet-AMD can be treated with currently-marketed VEGF inhibitors such as Lucentis or Eylea, however, such products typically require frequent repeated injections in the eye, and patients often continue to suffer from the continued progression of the underlying dry-AMD disease process. Current estimated annual sales of VEGF inhibitors for the treatment of the wet form of AMD are estimated to be about $7 billion worldwide. The root cause of the larger problem of dry-AMD is believed to be the dysfunction of RPE cells. One of the most exciting therapeutic approaches to dry-AMD is the transplantation of healthy, young RPE cells to support and replace the patients old degenerating RPE cells and to head off the advancing atrophy before it reaches the fovea. One of the most promising sources of healthy RPE cells is cells derived from pluripotent stem cells.

About OpRegen

Cell Cure’s OpRegen consists of RPE cells that are produced using a proprietary process that drives the differentiation of human embryonic stem cells into high purity RPE cells. OpRegen is also xeno-free,” meaning that no animal products were used either in the derivation and expansion of the human embryonic stem cells or in the directed differentiation process. The avoidance of the use of animal products eliminates some safety concerns. OpRegen is formulated as a suspension of RPE cells. Preclinical studies in mice have shown that following a single subretinal injection of OpRegen as a suspension of cells, the cells can rapidly organize into their natural monolayer structure and survive throughout the lifetime of the animal. OpRegen will be an off-the-shelf allogeneic product provided to retinal surgeons in a final formulation ready for transplantation. Unlike treatments that require multiple injections into the eye, such as currently-marketed products like Lucentis and Eylea for wet-AMD, it is expected that OpRegen would be administered in a single procedure.

About Cell Cure Neurosciences Ltd.

Cell Cure Neurosciences Ltd. was established in 2005 as a subsidiary of ES Cell International Pte. Ltd. (ESI), now a subsidiary of BioTime, Inc. (NYSE MKT: BTX). Cell Cures second largest shareholder is HBL Hadasit Bio-Holdings, (TASE: HDST, OTC: HADSY). Cell Cure is located in Jerusalem, Israel on the campus of Hadassah Medical Center. Cell Cure’s mission is to become a leading supplier of human cell-based therapies for the treatment of retinal and neural degenerative diseases. Its technology platform is based on the manufacture of diverse cell products sourced from clinical-grade (GMP-compatible) human embryonic stem cells. Its current focus is the development of retinal pigment epithelial (RPE) cells for the treatment of age-related macular degeneration. Cell Cure’s major shareholders include BioTime, Inc., HBL Hadasit Bio-Holdings Ltd., Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA), and Asterias Biotherapeutics (OTCBB: ASTY). Additional information about Cell Cure can be found on the web at http://www.cellcureneurosciences.com. A video of a presentation by Cell Cures CEO Dr. Charles Irving is available on BioTimes website.

About BioTime

BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. BioTimes focus is on pluripotent stem cell technology based on human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTimes therapeutic and research products include a wide array of proprietary PureStem progenitors, HyStem hydrogels, culture media, and differentiation kits. BioTime is developing Renevia (a HyStem product) as a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications, and is planning to initiate a pivotal clinical trial around Renevia, in 2014. In addition, BioTime has developed Hextend, a blood plasma volume expander for use in surgery, emergency trauma treatment and other applications. Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ HealthCare Corporation, under exclusive licensing agreements.

Read more here:
BioTimes Subsidiary Cell Cure Neurosciences Ltd. Files an IND with the FDA for OpRegen Designed to Treat Patients …

Comments Off

LifeMap Sciences Announces Release and Commercial Availability of GeneAnalytics 1.0, a Powerful Gene Set Analysis …

ALAMEDA, Calif.–(BUSINESS WIRE)–LifeMap Sciences, Inc., a subsidiary of BioTime, Inc., announced today the commercial release of GeneAnalytics 1.0 at http://www.geneanalytics.com. GeneAnalytics is a powerful, yet easy to use, gene set analysis tool designed to help life scientists and biomedical researchers identify expression signatures and functionality of their experimental gene sets, and define their roles in various biological processes and in health and disease.

GeneAnalytics is powered by LifeMap Sciences popular integrated knowledgebase and discovery platform for biomedical research, which includes: GeneCards (http://www.genecards.org), the human gene database, LifeMap Discovery (http://discovery.lifemapsc.com), the embryonic development and stem cell database and MalaCards (http://www.malacards.org), the human disease database. LifeMap Sciences holds the exclusive worldwide license to market GeneCards and MalaCardsfrom Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science.

LifeMap Sciences Biomedical Knowledgebase enables GeneAnalytics to analyze experimental gene sets of interest and match them toexpression patterns in various cell types, diseases and pathways and functional groups. It can aid in the discovery ofmarkers for tissues, cells and diseases, investigation ofdiseasemechanisms and in exploration of relationships between compounds and gene networks to enhance drug discovery. It is also a unique tool for characterization of tissue samples and cultured cells, assessment of their purity and analysis ofoutcomes of cell differentiation experiments.

GeneAnalytics is a key component of LifeMap Sciences recently launched premium platform, GeneCards Plus. The platform also includes GeneALaCart (http://genealacart.genecards.org), the GeneCards batch querying application and VarElect (http://varelect.genecards.org), the Next Generation Sequencing phenotyper.

Ronit Shtrichman, Ph.D., Vice President of Biology at LifeMap Sciences said, We believe that leveraging our extensive information and knowledgebase on biological entities, such as genes, cells, pathways, compounds and diseases, and the connections between these various entities to power gene set analysis by GeneAnalytics will enable it to significantly enhance basic biomedical research, stem cell research and therapeutic discovery.

In the few months since weve launched the beta version of GeneAnalytics, weve had over 1,000 scientists from academia and industry use it in their research, said Yaron Guan-Golan, Head of Marketing at LifeMap Sciences. This is evidence that GeneAnalytics is a powerful research aid and we look forward to continuously improve its capabilities and features in upcoming releases, together with GeneALaCart and VarElect, our premium GeneCards Plus research tools.

About LifeMap Sciences, Inc.

LifeMap Sciences (www.lifemapsc.com) core technology and business is based on its Integrated Biomedical Knowledgebase and discovery platform for biomedical research, which currently includesGeneCards: the leading human gene database;LifeMap Discovery, the database of embryonic development, stem cell research and regenerative medicine;MalaCards, the human disease database; and GeneAnalytics, a novel gene set analysis tool which leverages our Integrated Biomedical Knowledgebase. LifeMaps products are used in more than 3,000 institutions including academia, research hospitals, patent offices, and leading biotechnology and pharmaceutical companies.

LifeMap Sciences intends to continually improve the quality of its products, and is pursuing several new Internet and informatics products with substantial, rapid-revenue growth potential, leveraging its existing products and their large user base of life scientists. LifeMap also intends to extend its offerings to the field of mobile health via its subsidiaryLifeMap Solutions, Inc.

About BioTime

Read more:
LifeMap Sciences Announces Release and Commercial Availability of GeneAnalytics 1.0, a Powerful Gene Set Analysis …

Comments Off